Albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-08 and is reviewed periodically as new material appears.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
== Function and mechanism == An amino acid contains an amino (NH2) group. A keto acid contains a keto (=O) group. In transamination, the NH2 group on one molecule is exchanged with the =O group on the other molecule. The amino acid becomes a keto acid, and the keto acid becomes an amino acid. Transaminases require the coenzyme pyridoxal phosphate, which is converted into pyridoxamine in the first half-reaction, when an amino acid is converted into a keto acid. Enzyme-bound pyridoxamine in turn reacts with pyruvate, oxaloacetate, or alpha-ketoglutarate, giving alanine, aspartic acid, or glutamic acid, respectively. Many transamination reactions occur in tissues, catalysed by transaminases specific for a particular amino/keto acid pair. The reactions are readily reversible, the direction being determined by which of the reactants are in excess. This reversibility can be exploited for synthetic chemistry applications to achieve the synthesis of valuable chiral amines. The specific enzymes are named from one of the reactant pairs, for example; the reaction between glutamic acid and pyruvic acid to make alpha ketoglutaric acid and alanine is called alanine transaminase and was originally called glutamic-pyruvic transaminase or GPT for short.
=== Cyberwarfare vs. cyber war === The term "cyberwarfare" is distinct from the term "cyber war". Cyberwarfare includes techniques, tactics and procedures that may be involved in a cyber war, but the term does not imply scale, protraction or violence, which are typically associated with the term "war", which inherently refers to a large-scale action, typically over a protracted period of time, and may include objectives seeking to utilize violence or the aim to kill. A cyber war could accurately describe a protracted period of back-and-forth cyber attacks (including in combination with traditional military action) between warring states. To date, no such action is known to have occurred. Instead, armed forces have responded with tit-for-tat military cyber actions. For example, in June 2019, the United States launched a cyber attack against Iranian weapons systems in retaliation to the shooting down of a US drone in the Strait of Hormuz.
== Bicun == Bicun is Simcere Pharmaceutical's prescription edaravone injection pharmaceutical for the treatment of strokes. Edaravone is a synthetic-free radical scavenger and has been proved to be effective. Edaravone protects the brain by eliminating excessive free radicals, which are highly reactive molecules occurring in the human body as a result of stroke, an excessive number of which could result in cell damage.
Sources: en.wikipedia.org
Peroxidases or peroxide reductases (EC number 1.11.1.x) are a large group of enzymes which play a role in various biological processes. They are named after the fact that they commonly break up peroxides, and should not be confused with other enzymes that produce peroxide, which are often oxidases.
== Function == 50S includes the activity that catalyzes peptide bond formation (peptidyl transfer reaction), prevents premature polypeptide hydrolysis, provides a binding site for the G-protein factors (assists initiation, elongation, and termination), and helps protein folding after synthesis.
=== Dihydrolipoyl dehydrogenase Binding protein (E3BP) === An auxiliary protein unique to most eukaryotes is the E3 binding protein (E3BP), which serves to bind the E3 subunit to the PDC complex. In the case of human E3BP, hydrophobic proline and leucine residues in the BP interact with the surface recognition site formed by the binding of two identical E3 monomers.
Primary: Sodium thiopental, 5 grams, intravenous Secondary: Midazolam, 10 mg, intramuscular; sufentanil, 450 micrograms, intramuscular; and/or hydromorphone, 40 mg, intramuscular In the brief for the U.S. courts written by accessories, the State of Ohio implies that they were unable to find any physicians willing to participate in the development of protocols for executions by lethal injection, as this would be a violation of medical ethics, such as the Geneva Promise, and such physicians would be thrown out of the medical community and shunned for engaging in such deeds, even if they could not lawfully be stripped of their license. On December 8, 2009, Kenneth Biros became the first person executed using Ohio's new single-drug execution protocol. He was pronounced dead at 11:47 am EST, 10 minutes after receiving the injection. On September 10, 2010, Washington became the second state to use the single-drug Ohio protocol with the execution of Cal Coburn Brown, who was proclaimed dead within two minutes after receiving the single-drug injection of sodium thiopental. Eight states (Arizona, Georgia, Idaho, Missouri, Ohio, South Dakota, Texas, and Tennessee) have used the single-drug execution protocol. The state of Washington used this single drug method only once, as it later abandoned the death penalty. Four additional states (Arkansas, Kentucky, Louisiana, and North Carolina) announced that they would switch to a single-drug protocol but, as of June 2025, had not executed anyone since switching protocols.
Sources: en.wikipedia.org
4'-Methyl-α-pyrrolidinopropiophenone (4-MePPP, MPPP or MαPPP) is a stimulant drug and substituted cathinone. It is structurally very similar to α-PPP, with only one added methyl group in the para position on the phenyl ring. 4-MePPP was sold in Germany as a designer drug in the late 1990s and early 2000s, along with a number of other pyrrolidinophenone derivatives. Although it has never achieved the same international popularity as its better-known relations α-PPP and MDPV, 4-MePPP is still sometimes found as an ingredient of grey-market "bath salt" blends such as "NRG-3".
John J. Abel Award Julius Axelrod Award Pharmacia-ASPET Award in Experimental Therapeutics Robert R. Ruffolo Career Achievement Award Travel Award for Pharmacology Educators Bernard B. Brodie Award in Drug Metabolism P.B. Dews Lifetime Achievement Award for Research in Behavioral Pharmacology Drug Metabolism Early Career Achievement Award Goodman and Gilman Award in Receptor Pharmacology Benedict R. Lucchesi Distinguished Lectureship in Cardiac Pharmacology Torald Sollmann Award in Pharmacology Paul M. Vanhoutte Distinguished Lectureship in Cardiovascular Pharmacology Travel awards to participate in its meetings are also given to students and postdocs. Chemotherapy Clinical pharmacology Drug metabolism Neuropharmacology Pharmacology Toxicology Official website Molecular Interventions magazine
Naturally occurring ruthenium (44Ru) is composed of seven stable isotopes: 96, 98-102, 104 (of which the first and last may in the future be found radioactive). Additionally, 27 synthetic radioactive isotopes have been discovered. Of these radioisotopes, the most stable are 106Ru with a half-life of 371.8 days or 1.018 years, 103Ru, with a half-life of 39.245 days, and 97Ru with a half-life of 2.837 days. The other known isotopes run from 87Ru to 120Ru, and most of these have half-lives that are less than five minutes, except 94Ru (51.8 minutes), 95Ru (1.607 hours), and 105Ru (4.44 hours). The primary decay mode before the most abundant isotope, 102Ru, is electron capture to isotopes of technetium, and after beta emission to isotopes of rhodium. Double beta decay is the allowed mode for the two observationally stable isotopes: 96Ru and 104Ru. Because of the volatility of ruthenium tetroxide (RuO4), ruthenium isotopes with relatively short half-life are considered the next most hazardous airborne isotopes, after iodine-131, in case of release by a nuclear accident. The two most important isotopes of ruthenium so released are those with the longest half-life: 103Ru 106Ru.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。